Skip to main content

Table 1 Plasma drug concentrations and laboratory test values

From: Abnormally high plasma concentrations of M-4, the active metabolite of edoxaban, at the onset of acute kidney injury in a patient receiving rifampin and clarithromycin: a case report

 

Post-operative day

6

9

10

11

14

131

233

Time from last administration of edoxaban tablet to blood collection (h)

-

24

8

24

96

26

2

Plasma concentration of edoxaban (ng/mL)

-

131.1

796.2

116.1

 < 5.0

 < 5.0

413.2

Plasma concentration of M-4 (ng/mL)

-

115.8

878.5

216.2

2.1

 < 2.0

189.7

M-4 ratio (%)

-

88.3

110.3

186.2

-

-

45.9

Plasma concentration of coproporphyrin-I (ng/mL)

2.4

4.6

7.4

6.0

0.8

0.6

1.0

Plasma concentration of valsartan (µg/mL)

2.4

5.7

9.4

10.4

1.4

1.0

-b

Plasma concentration of IL-6 (pg/mL)

18.0

20.1

76.0

23.6

7.2

5.2

 < 3.1

Serum C-reactive protein (mg/L)

66.4

50.5

64.2

147.1

17.4

6.0

14.0

Serum creatinine (mg/dL)

0.88

1.20

2.21

2.32

0.96

0.89

0.89

Creatinine clearancea (mL/min)

62.5

46.3

25.1

23.9

57.8

59.0

62.4

Body weight (kg)

55.5

-

-

-

-

52.5

58.0

  1. The plasma concentrations of edoxaban, M-4, CP-I and valsartan were measured by UPLC-MSMS, and those of IL-6 by Human IL-6 Quantikine ELISA Kit (R&D Systems, Inc.)
  2. CP-I coproporphyrin-I, IL-6 interleukin-6
  3. aCreatinine clearance estimated by the Cockcroft-Gault formula
  4. bValsartan was discontinued between POD131 and 233